Trial Profile
Use of Eylea for the Treatment of an Optic Nerve Hemangioma
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 11 Aug 2017
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Haemangioma; Optic nerve disorders; Retinal disorders
- Focus Expanded access; Therapeutic Use
- 07 Aug 2017 Status changed from recruiting to completed.
- 06 Jan 2016 Status changed from not stated to recruiting.
- 06 Jun 2015 New trial record